Prevnar 20 and Menveo One-Vial Now Available for Ordering

Dear VFC Provider,

The VFC Program is now offering Prevnar 20® and Menveo® one-vial vaccines for ordering. A letter detailing clinical recommendations for each vaccine will be sent in the near future.

**Prevnar 20® Pneumococcal Conjugate Vaccine (Pfizer)**

Prevnar 20® builds on Prevnar 13® and includes seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.
Prevnar 20® is now available for ordering through the VFC Program, replacing Prevnar 13® which can no longer be requested. If you have any remaining supply of Prevnar 13®, continue to vaccinate your patients with your existing stock until you are ready to order more pneumococcal conjugate vaccine. Once you have administered most of your remaining Prevnar 13® and are ready to order Prevnar 20®, you may submit a VFC vaccine order even if this is prior to your routine order frequency. Orders of Prevnar 13® that have already been submitted but not yet approved will automatically be switched to Prevnar 20®. Vaccine requests will continue to be reviewed and approved based on existing on-hand inventory and usage.

**Menveo® one-vial MenACWY vaccine (GSK)**

The Menveo® one-vial presentation (10 pack) does not require reconstitution and is approved for use in persons 10 years through 55 years. The existing Menveo® two-vial presentation (5 pack) requires reconstitution and is approved for use in persons aged 2 months through 55 years.

The new Menveo® one-vial is now available for ordering through the VFC Program. However, the existing Menveo® two-vial presentation will be available in limited amounts, and it will be important to target this product for use in children aged 2 months through 2 years of age at high risk for Meningococcal disease. This product is the only meningococcal conjugate vaccine approved for use in this age group. Requests for the limited Menveo® two-vial vaccine will have a minimum order size of 1 dose with a maximum request of 5 doses.

Orders of Menveo® two-vial that have already been submitted but not yet approved will automatically be switched to the Menveo® one-vial presentation.
Transition to New Vaccines

Since Prevnar 20® is replacing Prevnar 13® and Menveo® one-vial should be ordered routinely instead of Menveo® two-vial, you are not required to submit a “Provider Request Form to Update Vaccine Brand Products Administered.” However, if you are using a different pneumococcal conjugate vaccine or a different meningococcal conjugate vaccine and would like to switch to these new products, please submit the form to the VFC Program.

Thank you,

California Department of Public Health | Immunization Branch
Vaccines for Children (VFC) Program
850 Marina Bay Parkway
Richmond, CA 94804
Phone: 877-2GET-VFC (877-243-8832)
Fax: 877-FAXX-VFC (877-329-9832)
Email: MyVFCVaccines@cdph.ca.gov